Biocryst Pharmaceuticals (BCRX) Revenue Growth (1y) (2011 - 2026)
Biocryst Pharmaceuticals (BCRX) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | -0.81% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | -0.24% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 0.07% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | -1.92% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 4.88% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 39.49% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 10.23% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.45 Bn | 2.10 Bn | 214.41 Mn | 33.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.61% |
| Mar 31, 2026 | 7.48% |
| Dec 31, 2025 | -99.46% |
| Sep 30, 2025 | 36.14% |
| Jun 30, 2025 | 49.41% |
| Mar 31, 2025 | 56.89% |
| Dec 31, 2024 | 40.83% |
| Sep 30, 2024 | 34.98% |
| Jun 30, 2024 | 32.54% |
| Mar 31, 2024 | 34.87% |
| Dec 31, 2023 | 17.42% |
| Sep 30, 2023 | 14.39% |
| Jun 30, 2023 | 25.88% |
| Mar 31, 2023 | 37.77% |
| Dec 31, 2022 | 68.68% |
| Sep 30, 2022 | 84.97% |
| Jun 30, 2022 | 31.17% |
| Mar 31, 2022 | 161.94% |
| Dec 31, 2021 | 1,074.25% |
| Sep 30, 2021 | 571.81% |